Neutrolis Inc

Neutrolis Inc

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://neutrolis.com

Last Round

VC Round

Jul 8, 2025

Total Funding Raised

$33.46M

Momentum Score

25 /100

Company Overview

Neutrolis Inc is a biotechnology company that develops precision therapies for autoimmune and inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

neutrophil extracellular trapsNETsautoimmune disease therapynon-immunosuppressive therapyengineered enzymesbiologic therapiesNET degradationprotein engineeringDNASE1L3 analogueexDNASE platformlupus therapyrheumatoid arthritis therapyclinical-stage biotechdry eye disease treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neutrolis Inc Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Neutrolis Inc Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundJul 8, 2025
VC RoundFeb 28, 2025
Series ADec 3, 2021
GrantJul 15, 2020

Key People

Founding team and executive leadership

Abdul R

Co-Founder, Co-President COO

Founding Team

Toby Fox

Co-founder, Chief Executive Officer

Founding Team

Sean McElduff

CFO

Executive Team

Neutrolis Inc Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors increased 46% MoM.

  • Apr 15, 2026

    Caren Deardorf appointed as Chief Business & Strategy Officer.

Neutrolis Inc Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neutrolis Inc Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neutrolis Inc's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range15
Year Founded2017
Last FundingJul 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.